N-(naphthalen-2-yl)-4-nitrobenzamide | 105772-57-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(naphthalen-2-yl)-4-nitrobenzamide
• 英文别名: N-2-naphthalenyl-4-nitrobenzamide；Benzamide, N-2-naphthalenyl-4-nitro-；N-naphthalen-2-yl-4-nitrobenzamide
• CAS: 105772-57-4
• 化学式: C₁₇H₁₂N₂O₃
• mdl: MFCD00409568
• 分子量: 292.294
• InChiKey: UEXONOVXGVTNOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(naphthalen-2-yl)-4-nitrobenzamide 在 溶剂黄146 、 锌 作用下， 反应 1.5h， 以80%的产率得到4-Amino-N-2-naphthalenylbenzamide
  参考文献：
  名称：

  Synthesis of New Congeners of 1-methyl-3-aminoisoquinolines, Evaluation of Their Cytotoxic Activity,In SilicoandIn VitroStudy of Their Molecular Targets as PDE4B

  摘要：

  To examine the cytotoxic activity of congeners of 3‐amino‐isoquinoline, we performed the phenotypic screening using panel of 60 cell lines and found that (N‐(6,7‐dimethoxy‐1‐methyl‐isoquinolin‐3‐yl)‐4‐{[(1‐ethyl‐4‐methyl‐1H‐pyrazol‐3‐yl)methyl]amino}benzamide (4d)) exhibited the significant effect against different tumor cell lines while showing the high activity toward human colorectal cancer HCT‐116 cells (IC50 = 18 μm) and human breast cancer T‐47D cells (GI50 = 1.9 μm). Virtual screening indicated that these compounds target protein kinases and phosphodiesterases (PDE). However, wet screening among panel of protein kinases did not show any significant activity. By contrast, 50 μm of 4c and 4d inhibited the growth of HKe3‐mtKRAS spheroids in the 3D floating (3DF) culture suggesting that 4c and 4d target PDE4B which is selectively upregulated by mtKRAS in 3DF culture.

  DOI：

  10.1111/cbdd.12691
• 作为产物：
  描述：

  对硝基苯甲酸 在 氯化亚砜 、 sodium carbonate 作用下， 以 乙醚 为溶剂， 生成 N-(naphthalen-2-yl)-4-nitrobenzamide
  参考文献：
  名称：

  N-苯甲酰基氨基萘的分子内电荷转移。1-氨基萘与2-氨基萘作为电子给体。

  摘要：

  制备了在苯甲酰基苯环的对位或间位具有不同取代基的N-（取代-苯甲酰基）-1-氨基萘和N-（取代-苯甲酰基）-2-氨基萘（1-NBA和2-NBA）使用类苯甲酰苯胺电荷转移作为探针反应，探测1-氨基萘（1-AN）和2-氨基萘（2-AN）之间的差异。对于在环己烷中所有制备的氨基萘衍生物，发现了异常的长波发射，并且通过观察到随着溶剂极性的增加或取代基的吸电子能力的增加而发生的大幅度红移，将其分配为CT状态。发现CT发射能量与取代基的Hammett常数和1-NBA（-0。45 eV高于2-NBA（-0.35 eV），后者与苯胺衍生物（BAs，-0.345 eV）接近。这表明在1-NBA的CT状态下，电荷分离的程度更高，其中完全放电分离是通过CT发射能量的线性下降率为-1.00的降低电势依赖性建立的。通过观察发现，当对位，间位和对位时，苯甲酰基取代的BA的相应线性斜率保持不变，从而排除了1-NBA和2

  DOI：

  10.1039/b210106h

文献信息

• [EN] SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122<br/>[FR] MODIFICATEURS À PETITE MOLÉCULE DE MICROARN MIR-122
  申请人：UNIV NORTH CAROLINA STATE

  公开号：WO2011091209A1

  公开（公告）日：2011-07-28

  MicroRNAs are a class of endogenous regulators of gene function. Aberrant regulation of microRNAs has been linked to various human diseases, most importantly cancer. Small molecule intervention of microRNA misregulation has the potential to provide new therapeutic approaches to such diseases. microRNA miR-122 is the most abundant microRNA in the liver and is involved in hepatocellular carcinoma development and hepatitis C virus (HCV) infection. Small molecule inhibitors and activators of the microRNA miR-122 are described, and methods for their identification are reported. These small molecule inhibitors reduce viral replication in liver cells and thus represent a new approach to the treatment of HCV infections. Moreover, small molecule activation of miR-122 in liver cancer cells selectively induced apoptosis through caspase activation, and thus has implications in cancer chemotherapy.

  微小RNA是一类内源性基因功能调节因子。微小RNA的异常调节与各种人类疾病有关，尤其是癌症。对微小RNA的小分子干预可能为这些疾病提供新的治疗途径。微小RNA miR-122是肝脏中最丰富的微小RNA，参与了肝细胞癌和丙型肝炎病毒（HCV）感染的发展。描述了微小RNA miR-122的小分子抑制剂和激活剂，并报告了其鉴定方法。这些小分子抑制剂可以减少肝细胞中的病毒复制，因此代表了治疗HCV感染的新方法。此外，在肝癌细胞中通过小分子激活miR-122可选择性诱导凋亡，通过激活半胱氨酸蛋白酶而在癌症化疗中具有重要意义。
• SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122
  申请人：Deiters Alexander

  公开号：US20130005759A1

  公开（公告）日：2013-01-03

  MicroRNAs are a class of endogenous regulators of gene function. Aberrant regulation of microRNAs has been linked to various human diseases, most importantly cancer. Small molecule intervention of microRNA misregulation has the potential to provide new therapeutic approaches to such diseases. microRNA miR-122 is the most abundant microRNA in the liver and is involved in hepatocellular carcinoma development and hepatitis C virus (HCV) infection. Small molecule inhibitors and activators of the microRNA miR-122 are described, and methods for their identification are reported. These small molecule inhibitors reduce viral replication in liver cells and thus represent a new approach to the treatment of HCV infections. Moreover, small molecule activation of miR-122 in liver cancer cells selectively induced apoptosis through caspase activation, and thus has implications in cancer chemotherapy.

  MicroRNAs是一类内源性基因调控因子。微小RNA的异常调控已与各种人类疾病，尤其是癌症相关联。小分子干预微小RNA的错调可能为这些疾病提供新的治疗方法。微小RNA miR-122是肝脏中最丰富的微小RNA，参与肝细胞癌的发展和丙型肝炎病毒（HCV）感染。描述了微小RNA miR-122的小分子抑制剂和激活剂，并报道了其鉴定方法。这些小分子抑制剂能够减少肝细胞中的病毒复制，因此代表了治疗HCV感染的新方法。此外，小分子激活miR-122在肝癌细胞中选择性地通过caspase激活诱导凋亡，因此在癌症化疗中具有重要意义。
• Small Molecule Modifiers of MicroRNA miR-122 Function for the Treatment of Hepatitis C Virus Infection and Hepatocellular Carcinoma
  作者：Douglas D. Young、Colleen M. Connelly、Christoph Grohmann、Alexander Deiters

  DOI：10.1021/ja910275u

  日期：2010.6.16

  MicroRNAs are a recently discovered new class of important endogenous regulators of gene function. Aberrant regulation of microRNAs has been linked to various human diseases, most importantly cancer. Small molecule intervention of microRNA misregulation has the potential to provide new therapeutic approaches to such diseases. Here, we report the first small molecule inhibitors and activators of the liver-specific microRNA miR-122. This microRNA is the most abundant microRNA in the liver and is involved in hepatocellular carcinoma development and hepatitis C virus (HCV) infection. Our small molecule inhibitors reduce viral replication in liver cells and represent a new approach to the treatment of HCV infections. Moreover, small molecule activation of miR-122 in liver cancer cells selectively induced apoptosis through caspase activation, thus having implications in cancer chemotherapy. In addition to providing a new approach for the development of therapeutics, small molecule modifiers of miR-122 function are unique tools for exploring miR-122 biogenesis.
• Anticonvulsant agents
  申请人：ELI LILLY AND COMPANY

  公开号：EP0194884B1

  公开（公告）日：1989-03-08
• HCV Combination Therapy
  申请人：Hodges Michael

  公开号：US20140127159A1

  公开（公告）日：2014-05-08

  The present invention relates to the treatment of hepatitis C (HCV) infection by the combination treatment with a miR-122 inhibitor and a HCV NS3/4A protease inhibitor.